[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligohydramnios\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligohydramnios":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100285569","pprom-registry-preterm-premature-rupture-of-membranes-100285569",false,"NCT02997345","PPROM Registry (Preterm Premature Rupture of Membranes)","Patient Registry for Women Diagnosed With Preterm Premature Rupture of Membranes or PPROM During Pregnancy","Inclusion Criteria:\n\n* Women diagnosed with Preterm Premature Rupture of Membranes (PPROM) prior to 37 weeks of pregnancy\n\nExclusion Criteria:\n\n* Those without a clinical diagnosis or confirmation of PPROM in pregnancy\n* Diagnosis of PROM beyond 37 weeks of pregnancy",true,"FEMALE","14 Years","55 Years",{"count":21,"type":22},3000,"ESTIMATED","1 Year","OBSERVATIONAL","Preterm Premature Rupture of Membranes (PPROM) before 37 weeks of pregnancy is responsible for 40% of preterm births in the United States. The PPROM Registry aims to identify possible causes of PPROM, evaluate trends in expectant management, measure maternal and fetal care, and to review short term and long term outcomes of affected pregnancies and births.",[27,28,29,30],"Fetal Membranes, Premature Rupture","Preterm Premature Rupture of the Membranes","Oligohydramnios","Premature Birth",[32],"PPROM","RECRUITING","2026-03-13",{"date":36,"type":37},"2026-03-16","ACTUAL",{"date":39,"type":37},"2013-07",{"date":41,"type":22},"2030-12",{"name":43,"class":44},"American Alliance for pProm Support","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100603324","phase-2-comparison-between-treatments-of-oligohydramnios-100603324","NCT07135037","Comparison Between Treatments of Oligohydramnios","Efficacy of L- Arginine Versus Sildenafil in Management of Idiopathic Oligohydramnios","Inclusion Criteria:\n\n* Pregnant women with gestational age between 26-37 weeks\n* Pregnant women whose age is \\\u003C 35 years\n* Woman with other indication for elective caesarean section.\n* Women carrying a single fetus with no major anomalies.\n* Initial amniotic fluid index \\\u003C8cm determined by reliable pelivabdominal ultrasound.\n\nExclusion Criteria:\n\n* Women complaining of other obstetric disorder such as, PPROM, preeclampsia, or diabetes.\n* Women with chronic illness such as, chronic hypertension, autoimmune disease or kidney disease.\n* Women who received other treatments for oligohydramnios in current pregnancy.\n* Women who smoke.\n* Fetuses with major congenital anomaly.","18 Years","35 Years",{"count":56,"type":22},40,"INTERVENTIONAL",[59],"PHASE2","Based on previous studies, Both sildenafil and L-arginine helped to improve idiopathic oligohydramnios.\n\nIn this study, Level of improvment of oligohydramnios will be compared. As well as, NICU admission to neonates of pregnancies complicated by idiopathic oligohydramnios. The end goal is to help physicians use the best drug for their patients.",[29],"2025-08-13",{"date":64,"type":37},"2025-08-21",{"date":66,"type":37},"2024-09-01",{"date":68,"type":22},"2025-12-31",{"name":70,"class":44},"Kafrelsheikh University",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":57,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100442620","fetal-growth-abnormality-detection-trial-100442620","NCT05043753","\"Fetal gRowth AbnorMality dEtection Trial\"","Department of Obstetrics and Gynecology Modena Policlinico Hospital Vial Del Pozzo 71, 41125 Modena","FRAME","Inclusion Criteria:\n\n* Maternal age ≥ 18 years and ability to give informed consent.\n* Singleton gestation\n* Ultrasound examination that confirms or revises the EDD before 14 weeks of gestational age\n* Gestational age ≥ 35 weeks' gestation\n* Normal aneuploidy screening (1st trimester screening, 2nd trimester screening, integrated screening, NIPT) when performed\n* Spontaneously conceived pregnancy (i.e the current pregnancy is not the result of in vitro fertilization)\n\nExclusion Criteria:\n\n* Fetal chromosomal or genetic abnormalities if invasive prenatal diagnosis is performed\n* Fetal malformations or soft markers identified on fetal anatomy survey\n* Episodes of uterine bleeding after 24 weeks gestation. Unobserved self-reported bleeding with confirmed intact pregnancy on ultrasound after the bleeding episode is not an exclusion criteria.\n* Uterine\u002Fplacental abnormalities including uterine malformations (i.e bicornuate uterus, didelpus uterus), abnormal placentation (placenta previa, accreta, percreta), uterine fibroids.\n* Cerclage in the current pregnancy\n* History of intrauterine fetal demise\n* History of fetal growth restriction or birth weight \\> 4Kg in a previous pregnancy\n* Fetal isoimmunization or alloimmunization\n* Fetal demise in previous pregnancies\n* Cancer (including melanoma but excluding other skin cancers). Dysplastic or pre-neoplatic conditions such as cervical intraepithelial neoplasia are admissible.\n* Endocrine disease including thyroid disease (recently diagnosed or whose medication dose is not stable), adrenal disease, diabetes mellitus (pregestational and gestational).\n* Renal disease with altered renal function (creatinine \\> 0.9, proteinuria \\> 300 mg\u002F24 hour)\n* Epilepsy or other seizure disorder\n* Any collagen disease (lupus erythematosus, scleroderma, etc.)\n* Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes). Liver disorders accounting for cholestasis (including cholestasis of pregnancy) if diagnosed prior to enrollment.\n* Hematological disorder including alloimmune and isoimmune thrombocytopenia but excluding mild iron deficiency anemia (Hb \\> 9 gm\u002Fdl). Patients with sickle cell disease are excluded.\n* Chronic pulmonary disease including asthma requiring regular use of medication and active TB. An asthma inhaler used on an as needed basis for a cold or an asthma attack is not considered regular use.\n* Heart disease except mitral value prolapse not requiring medication\n* Cardiovascular disorders: chronic hypertension, gestational hypertension or preeclampsia diagnosed prior to enrollment\n* Infectious diseases: HIV, CMV, toxoplasmosis, parvovirus B19, HBV, HCV\n* Chronic treatments with medications such as aspirin, steroids, anti-hypertensive agents, immunosuppressants, antineoplastic drugs.\n* Prior laparoscopic or open uterine surgeries where the uterine cavity was entered (such as myomectomies)\n* Resectoscopic myomectomies (prior resectoscopic polypectomies are not contraindications)\n* Prior classical cesarean deliveries.","45 Years",{"count":82,"type":22},1566,[84],"NA","The present trial intends to assess the diagnostic accuracy of symphysis fundal height (SFH) as opposed to SFH combined with point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC) in identifying small and large for gestational age infants (SGA and LGA infants) among low-risk pregnant women cared for by midwives after 35 weeks' gestation.\n\nLow risk pregnancies will be evaluated at 35-38, 40, 41, and 41+ weeks' gestation by midwives trained in SFH measurement and POC-US. Formal obstetric US performed by a perinatologist (i.e high risk obstetrician) will be performed in case SFH and\u002For POC-US suspect fetal growth or amniotic fluid abnormalities. Prenatal evaluations will be compared to actual birthweights.",[87,88,29,89],"Small for Gestational Age Infant","Large for Gestational Age Infant","Polyhydramnios","2024-12-04",{"date":92,"type":37},"2024-12-09",{"date":94,"type":37},"2024-01-20",{"date":96,"type":22},"2025-12-21",{"name":98,"class":44},"University of Modena and Reggio Emilia"]